When the causal mutation is known, the challenge shifts from identifying disease origins to defining its detectable beginning ...

Background Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple ...

Background Autosomal dominant Alzheimer’s disease (ADAD) serves as a model for presymptomatic biomarker discovery.

Register studies (Wimberly et al ) reveal the long-lasting educational disadvantage of childhood epilepsy but unexpected sex ...

Background Published cases of iatrogenic cerebral amyloid angiopathy (iCAA) are increasing; however, their geographic ...

Background Information about the incidence of cerebral cavernous malformations (CCM) is sparse and the effect of increasing MRI availability is uncertain. Our objective was to assess the incidence of ...

Objective This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 (‘Study 19’) to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic ...

Department of Neurology, Walton Centre for Neurology and Neurosurgery, Rice Lane, Liverpool, UK Dr PRD Humphrey, Department of Neurology, Walton Centre for Neurology and Neurosurgery, Rice Lane, ...

Background The role of physical activity in the risk of amyotrophic lateral sclerosis (ALS) is debated. It is also unclear whether the association differs in people at high genetic risk of ALS.

Background Cerebellar ataxias are the result of diverse disease processes that can be genetic or acquired. Establishing a diagnosis requires a methodical approach with expert clinical evaluation and ...

Background Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). Methods Patients with relapse-onset MS treated with ocrelizumab, ...

Department of Psychology, Institute of Psychiatry, Kings College, London, UK Correspondence to: Dr E Watkins, Department of Psychology, Institute of Psychiatry, De Crespingny Park, Denmark Hill, ...